Developer docs
API playgroundTry for free, no card

Search company profiles

StimLabs, LLC

Full company profile

uuid0008t98

Namestring
StimLabs, LLC
Legal namestring
Stimlabs LLC
Websiteurl
stimlabs.net
Company typeenum
Private
Founded yearint
2016
Descriptiontext

StimLabs, LLC is a private regenerative medicine company founded in 2015 and headquartered in Roswell, Georgia, that develops and commercializes placental tissue-based and collagen scaffold products for wound care applications. The company maintains a portfolio of 10 products organized into office-based solutions (Allacor P, Derma-Gide, Relese, Revita, Cogenex) and hospital-based solutions (Architect Fx, Corplex P, Vialize, Enverse, Revita Burn Clear), with five products holding FDA 510(k) clearance. Core technology centers on proprietary placental tissue processing methods, including dehydrated human umbilical cord particulate (dHUCP) and dehydrated chorionic human placental membrane (dCHPM) technologies, used for chronic wound management, diabetic foot ulcers, surgical wound dehiscence, and burn care. Most recently, StimLabs expanded into collagen scaffold particulates through the FDA-cleared DermaForm device, co-developed with Swiss regenerative medicine leader Geistlich.

StimLabs operates a B2B medical device sales model targeting healthcare providers and physicians (primary segment) and hospitals and clinical facilities (secondary segment), with use cases spanning wound care, chronic wound management, acute surgical wounds, diabetic foot ulcers, and burn care. Distribution is conducted through an authenticated provider portal (portal.stimlabs.com) with online payment capabilities, supported by content marketing through clinical case studies, physician and patient testimonials, and regulatory announcements. The company holds exclusive distribution rights for Geistlich's Derma-Gide and Harbor MedTech's Architect brands, and its own product and corporate trademarks (13+ registered, including StimLabs, Revita, Cogenex, Enverse, Vialize, Relese, Clearify, Corplex P, Theracor, Allacor P, and DermaForm) reinforce brand distinctiveness. Pricing is not publicly disclosed and follows a quote-based B2B medical device convention.

The company is led by founder and CEO John Daniel. It operates as an LLC domiciled in Georgia with no disclosed parent company, external private equity backing, or venture capital ownership despite an Investors page on the corporate website. Revenue is not publicly disclosed; the company sits in the 101-250 employee range, consistent with a mid-stage commercial regenerative medicine business competing in a soft tissue allograft market projected to reach $6.97B by 2030 at a 7.4% CAGR.

Short descriptiontext

StimLabs is a private regenerative medicine company that develops and sells FDA-cleared placental tissue and collagen scaffold products for wound care. It serves physicians, podiatrists, hospitals, and clinical facilities treating chronic wounds, diabetic foot ulcers, surgical wounds, and burns.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersRoswell, United States
HQ citystring
Roswell
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine, placental tissue products, wound care devices, soft tissue allografts, collagen scaffolds
Industry2 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine — Wound Care Devices
Social media profiles5 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeOne Time License
Description

StimLabs generates revenue through the sale of FDA 510(k) cleared regenerative medicine products including wound care devices, placental tissue products, and collagen scaffold devices sold to healthcare providers and hospitals.

stimlabs.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

StimLabs develops, manufactures, and distributes FDA 510(k)-cleared regenerative medicine products derived from placental tissue for wound care applications. The portfolio includes office-based solutions (Allacor P, Derma-Gide, Relese, Revita, Cogenex) for outpatient wound management and hospital-based solutions (Architect Fx, Corplex P, Vialize, Enverse, Revita Burn Clear) for acute and surgical wound care, sold to healthcare providers and clinical facilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Products demonstrated effective wound healing in clinical case studies including diabetic foot ulcers and surgical wound dehiscence
Product overview1 text field

StimLabs offers an innovative and comprehensive product portfolio of placental tissue-based regenerative medicine products designed for wound care applications. The portfolio is organized into two categories: Office-Based Solutions (Allacor P, Derma-Gide, Relese, Revita, Cogenex) for outpatient and clinic settings, and Hospital-Based Solutions (Architect Fx, Corplex P, Vialize, Enverse, Revita Burn Clear) for acute care environments. Several products hold FDA 510(k) clearance. The company recently expanded its portfolio with DermaForm, a collagen scaffold particulate wound care device developed in collaboration with Swiss partner Geistlich. All products leverage placental tissue technology for regenerative wound healing.

Product and service11 records
1Allacor P (510(k))
CategoryOffice-Based Wound Care Solutions
Description

Office-based placental tissue product for regenerative wound care applications, FDA 510(k) cleared and intended for physicians and outpatient clinics.

2Derma-Gide (510(k))
CategoryOffice-Based Wound Care Solutions
Description

Office-based wound care device derived from placental tissue, designed for soft tissue reconstruction. FDA 510(k) cleared; distributed by StimLabs and trademark of Geistlich Pharma AG.

3Relese
CategoryOffice-Based Wound Care Solutions
Description

Office-based placental tissue product for regenerative medicine applications, intended for outpatient and clinic settings.

4Revita
CategoryOffice-Based Wound Care Solutions
Description

Office-based placental tissue product for regenerative wound care applications, intended for outpatient and clinic use.

5Cogenex
CategoryOffice-Based Wound Care Solutions
Description

Office-based placental tissue product for regenerative medicine applications, intended for outpatient and clinic settings.

6Architect Fx (510(k))
CategoryHospital-Based Wound Care Solutions
Description

Hospital-based placental tissue product for surgical and wound care applications, FDA 510(k) cleared and intended for use in acute care environments.

7Corplex P (510(k))
CategoryHospital-Based Wound Care Solutions
Description

Hospital-based placental tissue product designed for complex wound management including diabetic foot ulcers and surgical wound dehiscence; uses dHUCP technology and is FDA 510(k) cleared.

8Vialize
CategoryHospital-Based Wound Care Solutions
Description

Hospital-based placental tissue product for regenerative medicine applications, intended for use in acute care and surgical environments.

9Enverse
CategoryHospital-Based Wound Care Solutions
Description

Hospital-based placental tissue product for regenerative wound care, intended for acute care settings.

10Revita Burn Clear
CategoryHospital-Based Wound Care Solutions
Description

Specialized hospital-based placental tissue product designed for burn wound management in acute care environments.

11DermaForm
CategoryWound Care Devices — Collagen Scaffold
Description

Collagen scaffold particulate wound care device designed for chronic and acute wounds. FDA 510(k) cleared; developed through collaboration with Geistlich Pharma AG.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-12
Description

StimLabs collaborated with Geistlich, a Swiss family-owned company and global leader in regenerative medicine, to obtain FDA 510(k) clearance for DermaForm, a collagen scaffold particulate wound care device. Geistlich is a co-development and technology partner providing collagen scaffold expertise for the product. The partnership represents a significant portfolio milestone for StimLabs in wound care solutions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MiMedx is a direct competitor in placental tissue-based regenerative medicine, offering amniotic membrane products (e.g., EpiFix, AmnioFix) for wound care and surgical applications. It is the most direct peer given its shared focus on dehydrated human amnion/chorion membrane technologies targeting the same clinical indications.

TypeBroad incumbent
Description

Stryker is a broad medical device incumbent that competes in surgical wound care, biologics, and orthopedics through its instruments and surgical solutions segments. Overlaps with StimLabs' hospital-based wound care products sold into surgical settings.

TypeBroad incumbent
Description

Integra LifeSciences is a broad incumbent in regenerative medicine and wound care, offering dermal regeneration templates (Integra Dermal Regeneration Template), amniotic products, and surgical devices. Overlaps with StimLabs in advanced wound care and tissue regeneration but operates across a much broader portfolio.

TypeBroad incumbent
Description

Convatec is a broad incumbent in advanced wound care and ostomy management, offering hydrocolloid and antimicrobial dressings plus skin barrier products. Relevant as a competitor for hospital and outpatient wound care budgets, though its portfolio emphasizes traditional dressings rather than biologic skin substitutes.

TypeBroad incumbent
Description

Coloplast is a broad incumbent in wound and skin care, with a Biatain product line targeting chronic wounds. Comparable in addressing diabetic foot ulcers and chronic wound management, but operates across ostomy, continence, and wound care rather than specializing in placental tissue biologics.

TypeBroad incumbent
Description

Smith+Nephew is a major global wound care incumbent offering advanced wound dressings, negative pressure wound therapy, and skin substitutes. Competes in the same hospital and office-based channels but operates as a diversified medical device company rather than a placental tissue specialist.

TypeDirect peer
Description

Organogenesis is a direct peer in advanced wound care biologics, offering Apligraf and Dermagraft (living cell-based skin substitutes) for chronic wounds. Competes in the same physician office and hospital channels with overlapping indications such as diabetic foot ulcers and venous leg ulcers.

8Amniox Medical (TissueTech)
TypeDirect peer
Description

Amniox Medical (part of TissueTech) is a direct peer specializing in cryopreserved amniotic membrane and umbilical cord tissue products (e.g., NEOX, CLARIX) for wound healing and surgical applications. Highly comparable given the shared use of human placental tissue for regenerative wound care.

TypeEmerging player
Description

Vericel is an emerging player in cellular therapies and specialty biologics for wound care and surgical repair, including MACI for cartilage repair. Comparable as a smaller, specialized regenerative medicine company competing in adjacent indications within hospital channels.

TypeDirect peer
Description

AlloSource is a direct peer as a non-profit allograft provider offering placental tissue and dermal products for wound care and surgical applications. Comparable in tissue processing technology and customer base of hospitals and surgeons.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

StimLabs, LLC

Regenerative Medicine — Wound Care Devicesstimlabs.net

StimLabs is a private regenerative medicine company that develops and sells FDA-cleared placental tissue and collagen scaffold products for wound care. It serves physicians, podiatrists, hospitals, and clinical facilities treating chronic wounds, diabetic foot ulcers, surgical wounds, and burns.

What StimLabs, LLC does

StimLabs, LLC is a private regenerative medicine company founded in 2015 and headquartered in Roswell, Georgia, that develops and commercializes placental tissue-based and collagen scaffold products for wound care applications. The company maintains a portfolio of 10 products organized into office-based solutions (Allacor P, Derma-Gide, Relese, Revita, Cogenex) and hospital-based solutions (Architect Fx, Corplex P, Vialize, Enverse, Revita Burn Clear), with five products holding FDA 510(k) clearance. Core technology centers on proprietary placental tissue processing methods, including dehydrated human umbilical cord particulate (dHUCP) and dehydrated chorionic human placental membrane (dCHPM) technologies, used for chronic wound management, diabetic foot ulcers, surgical wound dehiscence, and burn care. Most recently, StimLabs expanded into collagen scaffold particulates through the FDA-cleared DermaForm device, co-developed with Swiss regenerative medicine leader Geistlich.

StimLabs operates a B2B medical device sales model targeting healthcare providers and physicians (primary segment) and hospitals and clinical facilities (secondary segment), with use cases spanning wound care, chronic wound management, acute surgical wounds, diabetic foot ulcers, and burn care. Distribution is conducted through an authenticated provider portal (portal.stimlabs.com) with online payment capabilities, supported by content marketing through clinical case studies, physician and patient testimonials, and regulatory announcements. The company holds exclusive distribution rights for Geistlich's Derma-Gide and Harbor MedTech's Architect brands, and its own product and corporate trademarks (13+ registered, including StimLabs, Revita, Cogenex, Enverse, Vialize, Relese, Clearify, Corplex P, Theracor, Allacor P, and DermaForm) reinforce brand distinctiveness. Pricing is not publicly disclosed and follows a quote-based B2B medical device convention.

The company is led by founder and CEO John Daniel. It operates as an LLC domiciled in Georgia with no disclosed parent company, external private equity backing, or venture capital ownership despite an Investors page on the corporate website. Revenue is not publicly disclosed; the company sits in the 101-250 employee range, consistent with a mid-stage commercial regenerative medicine business competing in a soft tissue allograft market projected to reach $6.97B by 2030 at a 7.4% CAGR.

StimLabs, LLC firmographics

Firmographics
Name
StimLabs, LLC
Legal name
Stimlabs LLC
Website
https://stimlabs.net
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
StimLabs is a private regenerative medicine company that develops and sells FDA-cleared placental tissue and collagen scaffold products for wound care. It serves physicians, podiatrists, hospitals, and clinical facilities treating chronic wounds, diabetic foot ulcers, surgical wounds, and burns.
Ownership category
akta.pro rank

StimLabs, LLC industry classification

Industry
Product category
Regenerative Medicine — Wound Care Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative medicine
  • Placental tissue products
  • Wound care devices
  • Soft tissue allografts
  • Collagen scaffolds

Where StimLabs, LLC is headquartered

Location

Headquarters

HQ city
Roswell
HQ country
United States
HQ region
North America

Offices1 record

Markets served

StimLabs, LLC business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Medical Device Sales: StimLabs generates revenue through the sale of FDA 510(k) cleared regenerative medicine products including wound care devices, placental tissue products, and collagen scaffold devices sold to healthcare providers and hospitals.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

StimLabs, LLC product offering

Product offering

Core offering

StimLabs develops, manufactures, and distributes FDA 510(k)-cleared regenerative medicine products derived from placental tissue for wound care applications. The portfolio includes office-based solutions (Allacor P, Derma-Gide, Relese, Revita, Cogenex) for outpatient wound management and hospital-based solutions (Architect Fx, Corplex P, Vialize, Enverse, Revita Burn Clear) for acute and surgical wound care, sold to healthcare providers and clinical facilities.

Product overview

StimLabs offers an innovative and comprehensive product portfolio of placental tissue-based regenerative medicine products designed for wound care applications. The portfolio is organized into two categories: Office-Based Solutions (Allacor P, Derma-Gide, Relese, Revita, Cogenex) for outpatient and clinic settings, and Hospital-Based Solutions (Architect Fx, Corplex P, Vialize, Enverse, Revita Burn Clear) for acute care environments. Several products hold FDA 510(k) clearance. The company recently expanded its portfolio with DermaForm, a collagen scaffold particulate wound care device developed in collaboration with Swiss partner Geistlich. All products leverage placental tissue technology for regenerative wound healing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Allacor P (510(k)) Office-based placental tissue product for regenerative wound care applications, FDA 510(k) cleared and intended for physicians and outpatient clinics.
  • Derma-Gide (510(k)) Office-based wound care device derived from placental tissue, designed for soft tissue reconstruction. FDA 510(k) cleared; distributed by StimLabs and trademark of Geistlich Pharma AG.
  • Relese Office-based placental tissue product for regenerative medicine applications, intended for outpatient and clinic settings.
  • Revita Office-based placental tissue product for regenerative wound care applications, intended for outpatient and clinic use.
  • Cogenex Office-based placental tissue product for regenerative medicine applications, intended for outpatient and clinic settings.
  • Architect Fx (510(k)) Hospital-based placental tissue product for surgical and wound care applications, FDA 510(k) cleared and intended for use in acute care environments.
  • Corplex P (510(k)) Hospital-based placental tissue product designed for complex wound management including diabetic foot ulcers and surgical wound dehiscence; uses dHUCP technology and is FDA 510(k) cleared.
  • Vialize Hospital-based placental tissue product for regenerative medicine applications, intended for use in acute care and surgical environments.
  • Enverse Hospital-based placental tissue product for regenerative wound care, intended for acute care settings.
  • Revita Burn Clear Specialized hospital-based placental tissue product designed for burn wound management in acute care environments.
  • DermaForm Collagen scaffold particulate wound care device designed for chronic and acute wounds. FDA 510(k) cleared; developed through collaboration with Geistlich Pharma AG.

Quantifiable outcome

  • Products demonstrated effective wound healing in clinical case studies including diabetic foot ulcers and surgical wound dehiscence

Companies that use StimLabs, LLC

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

StimLabs, LLC technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

StimLabs, LLC partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • GeistlichcoreTechnology or Integration · 12 February 2026StimLabs collaborated with Geistlich, a Swiss family-owned company and global leader in regenerative medicine, to obtain FDA 510(k) clearance for DermaForm, a collagen scaffold particulate wound care device. Geistlich is a co-development and technology partner providing collagen scaffold expertise for the product. The partnership represents a significant portfolio milestone for StimLabs in wound care solutions.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

StimLabs, LLC competitors and assessment

Company assessment

Direct peers

  • MiMedx Group: MiMedx is a direct competitor in placental tissue-based regenerative medicine, offering amniotic membrane products (e.g., EpiFix, AmnioFix) for wound care and surgical applications. It is the most direct peer given its shared focus on dehydrated human amnion/chorion membrane technologies targeting the same clinical indications.
  • Organogenesis: Organogenesis is a direct peer in advanced wound care biologics, offering Apligraf and Dermagraft (living cell-based skin substitutes) for chronic wounds. Competes in the same physician office and hospital channels with overlapping indications such as diabetic foot ulcers and venous leg ulcers.
  • Amniox Medical (TissueTech): Amniox Medical (part of TissueTech) is a direct peer specializing in cryopreserved amniotic membrane and umbilical cord tissue products (e.g., NEOX, CLARIX) for wound healing and surgical applications. Highly comparable given the shared use of human placental tissue for regenerative wound care.
  • AlloSource: AlloSource is a direct peer as a non-profit allograft provider offering placental tissue and dermal products for wound care and surgical applications. Comparable in tissue processing technology and customer base of hospitals and surgeons.

Broad incumbents

  • Stryker: Stryker is a broad medical device incumbent that competes in surgical wound care, biologics, and orthopedics through its instruments and surgical solutions segments. Overlaps with StimLabs' hospital-based wound care products sold into surgical settings.
  • Integra LifeSciences: Integra LifeSciences is a broad incumbent in regenerative medicine and wound care, offering dermal regeneration templates (Integra Dermal Regeneration Template), amniotic products, and surgical devices. Overlaps with StimLabs in advanced wound care and tissue regeneration but operates across a much broader portfolio.
  • Convatec: Convatec is a broad incumbent in advanced wound care and ostomy management, offering hydrocolloid and antimicrobial dressings plus skin barrier products. Relevant as a competitor for hospital and outpatient wound care budgets, though its portfolio emphasizes traditional dressings rather than biologic skin substitutes.
  • Coloplast: Coloplast is a broad incumbent in wound and skin care, with a Biatain product line targeting chronic wounds. Comparable in addressing diabetic foot ulcers and chronic wound management, but operates across ostomy, continence, and wound care rather than specializing in placental tissue biologics.
  • Smith+Nephew: Smith+Nephew is a major global wound care incumbent offering advanced wound dressings, negative pressure wound therapy, and skin substitutes. Competes in the same hospital and office-based channels but operates as a diversified medical device company rather than a placental tissue specialist.

Emerging players

  • Vericel: Vericel is an emerging player in cellular therapies and specialty biologics for wound care and surgical repair, including MACI for cartilage repair. Comparable as a smaller, specialized regenerative medicine company competing in adjacent indications within hospital channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

StimLabs, LLC social profiles

Digital presence

StimLabs, LLC financial estimates

Financial estimate

Revenue estimate

Valuation estimate

StimLabs, LLC leadership team

Management profile

Number of profiles

Profiles1 record

StimLabs, LLC funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

StimLabs, LLC M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StimLabs, LLC

What does StimLabs, LLC do?

StimLabs develops, manufactures, and distributes FDA 510(k)-cleared regenerative medicine products derived from placental tissue for wound care applications. The portfolio includes office-based solutions (Allacor P, Derma-Gide, Relese, Revita, Cogenex) for outpatient wound management and hospital-based solutions (Architect Fx, Corplex P, Vialize, Enverse, Revita Burn Clear) for acute and surgical wound care, sold to healthcare providers and clinical facilities.

Is StimLabs, LLC a public or private company?

StimLabs, LLC is a private company. It is classified as unknown and is currently operating.

When was StimLabs, LLC founded?

StimLabs, LLC was founded in 2016. It employs 101 to 250 people.

Where is StimLabs, LLC based?

StimLabs, LLC is headquartered in Roswell, United States, in the North America region.

How does StimLabs, LLC make money?

One revenue line is on record: medical Device Sales.

Who are StimLabs, LLC's main competitors?

Direct peers on record are MiMedx Group, Organogenesis, Amniox Medical (TissueTech) and AlloSource. Broad incumbents are Stryker, Integra LifeSciences, Convatec, Coloplast and Smith+Nephew. Vericel is listed as an emerging player.

Does StimLabs, LLC have an API?

No public API is recorded for StimLabs, LLC.

What industry is StimLabs, LLC in?

StimLabs, LLC's product category is Regenerative Medicine — Wound Care Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OpensecretsStimLabs LLC Lobbyists, 2025StimLabs LLC's 2025 lobbying roster lists named lobbyists from Senate LD-2 filings, with zero prior federal government employment. The page provides a sortable roster and counts named lobbyists per hiring entity, but no specific event or outcome is reported.ProskauerGeorgia Federal Court Denies TRO and Motion to Dismiss in Trade Secrets CaseA U.S. District Court in Georgia denied a former executive's motion to dismiss trade secret misappropriation claims brought by Stimlabs LLC, allowing the lawsuit to proceed despite rejecting a temporary restraining order. The court ruled that while the executive's document access may have been job-related, the complaint sufficiently alleged specific instances of misappropriation and breach of contract. This decision permits the employer to pursue discovery regarding the alleged theft of confidential product development data.Bloomberg Law NewsPodiatrist, Supplier Sue HHS Over Tissue Product Coverage DenialA Michigan-based podiatry practice, Macomb Foot, Ankle & Wound Care, and its supplier, StimLabs LLC, filed a lawsuit in the US District Court for the District of Columbia against the Biden administration. The plaintiffs allege that the Centers for Medicare & Medicaid Services (CMS) arbitrarily denied coverage for human cell and tissue-based products by misinterpreting FDA guidance to classify them as experimental.PR NewswireStimlabs® LLC Announces Launch of Relese® - A Uniquely Fenestrated Allograft for Chronic and Acute WoundsStimLabs LLC announced the launch of Relese, a fenestrated dehydrated complete human placental membrane allograft designed for chronic and acute wounds, marking an addition to the company's regenerative medicine portfolio. The product distinguishes itself through StimLabs' patented Clearify technology, which retains all three layers of native placental tissue rather than delaminating them, addressing a specific clinical need for highly exudating wounds. With this launch, StimLabs aims to expand its reach to more patients requiring placental membrane-derived wound care solutions.PR NewswireStimLabs, LLC. Announces Launch of Second Umbilical Cord Derived Product: Corplex™ PStimLabs announced the launch of Corplex P, a Wharton's Jelly allograft derived from donated human umbilical cord tissue intended for supplementation of connective tissue voids in open wound environments. The product, developed within approximately one year despite the COVID-19 pandemic, received Q Code Q4231 from the Centers for Medicare and Medicaid Services as of July 1, 2020. This marks StimLabs' second umbilical cord-derived product following the launch of Corplex in early Q1 2020, expanding the company's regenerative medicine portfolio.